Home Aimmune Therapeutics

Aimmune Therapeutics

acquired
Post-IPO Round
Developer of Characteristic Oral Desensitization Immunotherapy

Basic Information

Aimmune Therapeutics is a company operating in the U.S. biotechnology industry. Its primary focus is on developing candidate products for peanut and other food allergies. Our mission is to transform the lives of millions of people with severe food allergies. The company's treatment approach is known as Characterized Oral Desensitization Immunotherapy, a system designed to desensitize patients to food allergens using characterized biologics, defined treatment protocols, and support services.
Aimmune Therapeutics, Inc.
California,United States of America
101~500 people
January 01, 2011
jnormart@w2ogroup.com